

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

RELEVANT EVENT

Grifols has concluded the refinancing process of its financial debt for an amount of \$6.3Bn, except for the \$1Bn senior unsecured notes which will be refinanced shortly.

Grifols informs that Term Loan A ("**TLA**") amounts to \$3.3Bn issued at LIBOR+175bps with a 6 year tenor and quasi-bullet amortising structure. Likewise, Term Loan B ("**TLB**") amounts to \$3.0Bn at LIBOR+225bps; in this case tenor is 8 years and bullet amortization.

With the refinancing of these senior loans, in addition to extending the tenor, the Company has reduced the margin by c.100bps.

The refinancing includes \$1.7Bn devoted to the acquisition of Hologic's share of NAT donor screening unit that was closed last January 31st.

In Barcelona, on 6 February 2017

Nuria Martín Barnés
Secretary to the Board of Directors